A key heuristic for deciding between second-line endocrine therapy versus chemotherapy/ADC is the duration of benefit from the first-line CDK4/6 inhibitor. Patients who progress after a long duration (e.g., >18 months) are likely still endocrine-sensitive and should receive further endocrine-based therapy. Rapid progression (e.g., <6 months) suggests endocrine resistance, warranting a potential switch in modality.

Kaplan-Meier curves from the VICTORIA-1 trial show a steep, immediate drop-off for patients on fulvestrant monotherapy, with ~60% progressing quickly. In contrast, the giredestrant combination arms show a much flatter initial curve, visually demonstrating that a primary benefit is protecting the large subset of patients who would otherwise fail therapy very early.

With pirtobrutinib, time to next treatment often exceeds progression-free survival. This discrepancy exists because disease progression is frequently slow and asymptomatic, meaning clinicians do not need to switch therapies immediately upon seeing radiographic changes, allowing for longer treatment duration.

The Right Choice trial shows CDK4/6 inhibitors are safer and better at delaying cancer progression than chemotherapy for patients with visceral metastases. However, this advantage doesn't translate to longer overall survival, suggesting the key benefit is improved quality of life and a less complex treatment regimen rather than longevity.

A patient's time to progression on first-line CDK4/6 inhibitor therapy acts as an informal biomarker. A shorter duration, such as 14 months, is viewed by experts as "not so great" and indicates a degree of underlying endocrine resistance that influences subsequent treatment strategies.

The ideal candidate for single-agent oral SERD therapy after CDK4/6 inhibitor progression is well-defined. This patient profile includes having received over 12 months of benefit from the prior CDK4/6 inhibitor, being asymptomatic, and having disease progression confined to the bones, as this group derives significant benefit with lower toxicity.

Patients are often exhausted after primary treatment and surprised by the recommendation for two additional years of intensive oral therapy. Clinicians should introduce this possibility early in the treatment journey to manage expectations and prevent the patient from feeling overwhelmed later on.

New CDK inhibitors that also target CDK2 show great activity in models resistant to current CDK4/6 agents. Instead of being reserved for later use, they are already being tested in frontline trials. The strategy, similar to that of ALK inhibitors in lung cancer, is that using the best drug first may prevent or significantly delay the onset of resistance.

A simple clinical biomarker—having received a prior CDK4/6 inhibitor for over 12 months—identifies patients likely to achieve significant progression-free survival (nearly nine months) with single-agent elacestrant. This allows clinicians to select patients for monotherapy without complex genomic profiling.